These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 2720310)

  • 1. 5-HT3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret.
    Higgins GA; Kilpatrick GJ; Bunce KT; Jones BJ; Tyers MB
    Br J Pharmacol; 1989 May; 97(1):247-55. PubMed ID: 2720310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin-induced emesis in the Ferret: a new animal model.
    Florczyk AP; Schurig JE; Bradner WT
    Cancer Treat Rep; 1982 Jan; 66(1):187-9. PubMed ID: 7198011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reserpine, para-chlorophenylalanine and fenfluramine antagonise cisplatin-induced emesis in the ferret.
    Barnes JM; Barnes NM; Costall B; Naylor RJ; Tattersall FD
    Neuropharmacology; 1988 Aug; 27(8):783-90. PubMed ID: 2905784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of cisplatin- and m-chlorophenylbiguanide-induced emesis in ferrets.
    Kamato T; Ito H; Nagakura Y; Nishida A; Yuki H; Yamano M; Miyata K
    Eur J Pharmacol; 1993 Jul; 238(2-3):369-76. PubMed ID: 8405104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets.
    Tattersall FD; Rycroft W; Francis B; Pearce D; Merchant K; MacLeod AM; Ladduwahetty T; Keown L; Swain C; Baker R; Cascieri M; Ber E; Metzger J; MacIntyre DE; Hill RG; Hargreaves RJ
    Neuropharmacology; 1996; 35(8):1121-9. PubMed ID: 9121615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of high-affinity 5-HT3 receptor antagonists. 2. Two novel tricyclic benzamides.
    Youssefyeh RD; Campbell HF; Airey JE; Klein S; Schnapper M; Powers M; Woodward R; Rodriguez W; Golec S; Studt W
    J Med Chem; 1992 Mar; 35(5):903-11. PubMed ID: 1548679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of 5-HT3 receptor antagonists on cisplatin-induced emesis in the pigeon.
    Preziosi P; D'Amato M; Del Carmine R; Martire M; Pozzoli G; Navarra P
    Eur J Pharmacol; 1992 Oct; 221(2-3):343-50. PubMed ID: 1426010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The anti-emetic activity of GK-128 in Suncus murinus.
    Ito C; Isobe Y; Kijima H; Kiuchi Y; Ohtsuki H; Kawamura R; Tsuchida K; Higuchi S
    Eur J Pharmacol; 1995 Oct; 285(1):37-43. PubMed ID: 8846809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiemetic activity of FK1052, a 5-HT3- and 5-HT4-receptor antagonist, in Suncus murinus and ferrets.
    Nakayama H; Yamakuni H; Higaki M; Ishikawa H; Imazumi K; Matsuo M; Mutoh S
    J Pharmacol Sci; 2005 Aug; 98(4):396-403. PubMed ID: 16079468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Role of serotonin in emesis].
    Minami M; Endo T; Hirafuji M
    Nihon Yakurigaku Zasshi; 1996 Nov; 108(5):233-42. PubMed ID: 8974084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of dopamine D3 receptors in the area postrema in R(+)-7-OH-DPAT-induced emesis in the ferret.
    Yoshikawa T; Yoshida N; Hosoki K
    Eur J Pharmacol; 1996 Apr; 301(1-3):143-9. PubMed ID: 8773458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Granisetron, a 5-HT3 receptor antagonist, inhibited cisplatin-induced 5-hydroxytryptamine release in the isolated ileum of ferrets.
    Endo T; Ogawa T; Hamaue N; Akita K; Hirafuji M; Minami M; Blower PR
    Res Commun Mol Pathol Pharmacol; 1998 Jun; 100(3):243-53. PubMed ID: 9730004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotonin 5-HT3 receptor antagonists prevent cisplatin-induced emesis in Cryptotis parva: a new experimental model of emesis.
    Darmani NA
    J Neural Transm (Vienna); 1998; 105(10-12):1143-54. PubMed ID: 9928884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms by which cancer chemotherapeutic drugs induce emesis.
    Cubeddu LX
    Semin Oncol; 1992 Dec; 19(6 Suppl 15):2-13. PubMed ID: 1485177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotonin mechanisms in chemotherapy-induced emesis in cancer patients.
    Cubeddu LX
    Oncology; 1996 Jun; 53 Suppl 1():18-25. PubMed ID: 8692546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of 5-HT3 receptor antagonists on models of acute and delayed emesis induced by cisplatin in the ferret.
    Rudd JA; Naylor RJ
    Neuropharmacology; 1994 Dec; 33(12):1607-8. PubMed ID: 7760983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological characterization of RS 25259-197, a novel and selective 5-HT3 receptor antagonist, in vivo.
    Eglen RM; Lee CH; Smith WL; Johnson LG; Clark R; Whiting RL; Hegde SS
    Br J Pharmacol; 1995 Feb; 114(4):860-6. PubMed ID: 7773547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The broad-spectrum anti-emetic activity of AS-8112, a novel dopamine D2, D3 and 5-HT3 receptors antagonist.
    Yoshikawa T; Yoshida N; Oka M
    Br J Pharmacol; 2001 May; 133(2):253-60. PubMed ID: 11350861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A dual effect of some 5-HT3 receptor antagonists on cisplatin-induced emesis in the pigeon.
    Navarra P; Martire M; del Carmine R; Pozzoli G; Preziosi P
    Toxicol Lett; 1992 Dec; 64-65 Spec No():745-9. PubMed ID: 1471230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The actions of fenfluramine and interaction with 5-HT3 receptor-antagonists to inhibit emesis in the ferret.
    Costall B; Naylor RJ; Tattersall FD
    J Pharm Pharmacol; 1990 Feb; 42(2):94-101. PubMed ID: 1972409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.